title: [Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus].
abstract: OBJECTIVE
  To compare the therapeutic effect of portal vein stenting and endovascular implantation of iodine-125 seeds strand followed by transcatheter arterial chemoembolization combined with or without sorafenib in patients for hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT).
  
  
  METHODS
  A total of 53 patients with HCC complicated by MPVTT who received portal vein stenting and endovascular implantation of iodine-125 seeds strand followed by transcatheter arterial chemoembolization combined without (group A, n=38) or with (group B, n=15) sorafenib in Affiliated Yancheng Hospital of Southeast University Medical College during January 2010 and August 2015 were analyzed retropectively.Overal survival, progress free survival and procedure-related adverse event were compared between the two groups.
  
  
  RESULTS
  The technical success rate was 100% for placement of (125)I seeds strand and stent in the obstructed main portal vein.No serious procedure-related adverse events occurred. Median survival time of group A and B were 12.1 and 14.8 months, respectively (P=0.037). Additionally, Median progress free survival time of group A and B were 2.8 and 4.0 months, respectively (P=0.002).
  
  
  CONCLUSIONS
  Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined with sorafenib could improve the survival time, the progress free survival time of patients with HCC complicated by MPVTT.
authors.affiliation: Department of Interventional Radiology, Affiliated Yancheng Hospital of Southeast University Medical College, Yancheng 224001, China.
authors.forename: W W
authors.initials: WW
authors.lastname: Li
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Dai
authors.forename: H G
authors.initials: HG
authors.lastname: Wan
authors.forename: L Z
authors.initials: LZ
authors.lastname: Yao
authors.forename: J
authors.initials: J
authors.lastname: Zhu
authors.forename: C L
authors.initials: CL
authors.lastname: Li
authors.forename: X J
authors.initials: XJ
authors.lastname: Wang
authors.forename: J
authors.initials: J
authors.lastname: Pan
authors.forename: L Z
authors.initials: LZ
authors.lastname: Chen
mesh_terms: D001158:Arteries; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D003131:Combined Modality Therapy; D057510:Endovascular Procedures; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000628:therapy*; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D011169:Portal Vein / Q000503:physiopathology / Q000601:surgery*; D000077157:Sorafenib; D015607:Stents; D013927:Thrombosis; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib